Brainstorm Cell Therapeutics Inc. (BCLI)
Company Info
ISIN | US10501E2019 |
---|---|
CUSIP | 10501E201 |
Sector | Healthcare |
Industry | Biotechnology |
Highlights
Market Cap | $9.81M |
---|---|
EPS | -$0.42 |
EBITDA (TTM) | -$21.28M |
Year Range | $0.13 - $3.46 |
Target Price | $5.25 |
Short % | 8.09% |
Short Ratio | 3.10 |
Share Price Chart
Loading data...
Performance
The chart shows the growth of an initial investment of $10,000 in Brainstorm Cell Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Compare to other instruments
Return
Brainstorm Cell Therapeutics Inc. had a return of -87.79% year-to-date (YTD) and -86.19% in the last 12 months. Over the past 10 years, Brainstorm Cell Therapeutics Inc. had an annualized return of -21.57%, while the S&P 500 had an annualized return of 9.85%, indicating that Brainstorm Cell Therapeutics Inc. did not perform as well as the benchmark.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | -87.79% | 19.92% |
1 month | 16.32% | 5.06% |
6 months | -92.92% | 7.11% |
1 year | -86.19% | 16.17% |
5 years (annualized) | -42.06% | 11.84% |
10 years (annualized) | -21.57% | 9.85% |
Monthly Returns Heatmap
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023 | -1.38% | -27.72% | -10.68% | -7.07% | -88.30% | -23.54% | 82.35% |
Risk-Adjusted Performance
This table presents a comparison of risk-adjusted performance metrics for Brainstorm Cell Therapeutics Inc. (BCLI) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
---|---|---|---|---|---|
BCLI Brainstorm Cell Therapeutics Inc. | -0.58 | ||||
^GSPC S&P 500 | 1.25 |
Dividend History
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Brainstorm Cell Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Brainstorm Cell Therapeutics Inc. was 99.71%, occurring on Nov 2, 2023. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-99.71% | Jan 10, 2005 | 4658 | Nov 2, 2023 | — | — | — |
-50% | Nov 11, 2003 | 17 | May 21, 2004 | 46 | Nov 4, 2004 | 63 |
-13.33% | Jun 20, 2003 | 1 | Jun 20, 2003 | 1 | Jul 31, 2003 | 2 |
-9.53% | Jun 12, 2003 | 1 | Jun 12, 2003 | 1 | Jun 19, 2003 | 2 |
-9% | Jan 4, 2005 | 2 | Jan 5, 2005 | 1 | Jan 6, 2005 | 3 |
Volatility Chart
The current Brainstorm Cell Therapeutics Inc. volatility is 74.14%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.